Home » Analyst Says Crestor Likely Failed Dialysis Trial
Analyst Says Crestor Likely Failed Dialysis Trial
AstraZeneca Plc’s cholesterol drug Crestor likely failed to show benefit in a clinical trial assessing its use in dialysis patients, a leading analyst said.
Interactive Investor
Interactive Investor
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May